Long acting GLP-1 receptor agonist (injectable)
Bofanglutide 12 mg injection every 2 weeks
BOFANG_SC_12MG_Q2W
Effects across outcomes
Bayesian random effects estimate against the comparator of each analysis (usually placebo), posterior median and 95% credible interval. Green: clearly better; red: clearly worse.
| Condition | Outcome | Window | Versus | Effect (95% CrI) | SUCRA |
|---|---|---|---|---|---|
| Overweight or obesity without diabetes (adults) | Percent body weight change | weeks 20 to 40 (target week 26) | Placebo | MD -7.40 (-14.36 to 1.64) | 0.46 |
| Overweight or obesity without diabetes (adults) | Percent body weight change | weeks 20 to 40 (target week 26) | Placebo | MD -7.88 (-13.31 to 0.38) | 0.53 |
| Overweight or obesity without diabetes (adults) | SF-36 physical component summary change | weeks 20 to 130 (target week 52) | Placebo | MD 1.29 (-6.35 to 8.58) | 0.53 |
| Overweight or obesity without diabetes (adults) | Serious adverse events | longest follow-up | Placebo | HR 2.03 (0.24 to 15.59) | 0.36 |
| Overweight or obesity without diabetes (adults) | Nausea | longest follow-up | Placebo | HR 3.62 (1.58 to 9.03) | 0.50 |
| Overweight or obesity without diabetes (adults) | Vomiting | longest follow-up | Placebo | HR 1.93 (0.73 to 4.87) | 0.76 |
| Overweight or obesity without diabetes (adults) | Diarrhea | longest follow-up | Placebo | HR 1.46 (0.60 to 3.48) | 0.62 |